By Tom Kerr, CFA NASDAQ: CTSO READ THE FULL CTSO RESEARCH REPORT New Findings Presented at European Society of Cardiology (ESC) Congress 2026 On September 2, 2026, the CytoSorbents (NASDAQ: CTSO) announced an independent new patient-level matched analysis of real-world data demonstrating that intraoperative use of CytoSorb was associated with a significant reduction in severe perioperative